MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.omtm.2022.09.010

Медицинская библиотека · Molecular therapy. Methods & clinical development · 2022

IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy.

Liang Qiushi, Catalano Fabio, Vlaar Eva C, Pijnenburg Joon M, Stok Merel, van Helsdingen Yvette, Vulto Arnold G, van der Ploeg Ans T, van Til Niek P, Pijnappel W W M Pim

СтатьяПеревод пока не подготовлен

Аннотация

Pompe disease is caused by deficiency of acid α-glucosidase (GAA), resulting in glycogen accumulation in various tissues, including cardiac and skeletal muscles and the central nervous system (CNS). Enzyme replacement therapy (ERT) improves cardiac, motor, and respiratory functions but is limited by poor cellular uptake and its inability to cross the blood-brain barrier. Previously, we showed that hematopoietic stem cell (HSPC)-mediated lentiviral gene therapy (LVGT) with codon-optimized GAA (LV-GAAco) caused glycogen reduction in heart, skeletal muscles, and partially in the brain at high vector copy number (VCN). Here, we fused insulin-like growth factor 2 (IGF2) to a codon-optimized version of GAA (LV-IGF2.GAAco) to improve cellular uptake by the cation-independent mannose 6-phosphate/IGF2 (CI-M6P/IGF2) receptor. In contrast to LV-GAAco, LV-IGF2.GAAco was able to completely normalize glycogen levels, pathology, and impaired autophagy at a clinically relevant VCN of 3 in heart and skeletal muscles. LV-IGF2.GAAco was particularly effective in treating the CNS, as normalization of glycogen levels and neuroinflammation was achieved at a VCN between 0.5 and 3, doses at which LV-GAAco was largely ineffective. These results identify IGF2.GAA as a candidate transgene for future clinical development of HSPC-LVGT for Pompe disease.

Для цитирования: Liang Qiushi, Catalano Fabio, Vlaar Eva C, Pijnenburg Joon M, Stok Merel, van Helsdingen Yvette, Vulto Arnold G, van der Ploeg Ans T, van Til Niek P, Pijnappel W W M Pim. IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy.. Molecular therapy. Methods & clinical development. 2022. DOI: 10.1016/j.omtm.2022.09.010.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.